CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.110
-0.170 (-7.46%)
Sep 8, 2025, 10:51 AM - Market open
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $18.66M in the quarter ending June 30, 2025, a decrease of -25.71%. This brings the company's revenue in the last twelve months to $141.10M, up 18.01% year-over-year. In the year 2024, CytomX Therapeutics had annual revenue of $138.10M with 36.45% growth.
Revenue (ttm)
$141.10M
Revenue Growth
+18.01%
P/S Ratio
1.56
Revenue / Employee
$1,166,116
Employees
121
Market Cap
347.97M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CTMX News
- 11 days ago - CytomX Therapeutics to Present at Upcoming September Investor Conferences - GlobeNewsWire
- 26 days ago - CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study - GlobeNewsWire
- 4 weeks ago - CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - CytomX Therapeutics: Updated Outlook For Late 2025 - Seeking Alpha
- 4 weeks ago - CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 3 months ago - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 months ago - CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - GlobeNewsWire